Immunotherapeutics Global Market – Forecast To 2021

1 EXECUTIVE SUMMARY 16

2 INTRODUCTION 22

• 2.1 KEY TAKE AWAYS 22
• 2.2 REPORT DESCRIPTION 22
• 2.3 MARKETS COVERED 24
• 2.4 STAKEHOLDERS 25
• 2.5 RESEARCH METHODOLOGY 26
  • 2.5.1 MARKET SIZE ESTIMATION 27
  • 2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 30
  • 2.5.3 SECONDARY SOURCES 31
  • 2.5.4 PRIMARY SOURCES 32
  • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 32
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 34
  • 2.5.7 ASSUMPTIONS 34

3 MARKET ANALYSIS 36

• 3.1 INTRODUCTION 36
• 3.2 MARKET SEGMENTATION 37
• 3.3 FACTORS INFLUENCING MARKET 38
  • 3.3.1 DRIVERS AND OPPORTUNITIES 39
    • 3.3.1.1 Increasing incidence of immunological diseases such as cancer, autoimmune and infectious diseases 39
    • 3.3.1.2 High potency of (antibodies) over small molecule drugs 39
    • 3.3.1.3 Mutual agreements among companies from drug development to commercialization 40
    • 3.3.1.4 Increasing importance of cart therapies 40
    • 3.3.1.5 Adoption of biological therapies in disease management 41
    • 3.3.1.6 Emerging asia pacific and latin american countries engaged in the development, commercialization and distribution of immunotherapy

  drugs 42

  • 3.3.1.7 Increasing government funding 42
• 3.3.2 RESTRAINTS AND THREATS 43
  • 3.3.2.1 High cost of drug development process with a threat of failure in end stage 43
  • 3.3.2.2 Reimbursement issues 44

4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE 60

• 4.1 INTRODUCTION 60
• 4.2 MONOCLONAL ANTIBODIES 63
  • 4.2.1 NAKED MONOCLONAL ANTIBODIES 64
  • 4.2.2 CONJUGATED MONOCLONAL ANTIBODIES 66
    • 4.2.2.1 Radio-labeled antibodies 66
    • 4.2.2.2 Chemo-labeled antibodies 66
  • 4.2.3 BISPECIFIC MONOCLONAL ANTIBODIES 67
• 4.3 THERAPEUTIC VACCINES 68
• 4.4 CHECKPOINT INHIBITORS 72
• 4.5 NON-SPECIFIC IMMUNOTHERAPY 77
  • 4.5.1 CYTOKINES 78
  • 4.5.2 IMMUNOMODULATING DRUGS 79

5 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY APPLICATION 81

• 5.1 INTRODUCTION 81
• 5.2 ONCOLOGY 83
  • 5.2.1 LUNG CANCER 85
  • 5.2.2 MELANOMA 86
  • 5.2.3 HEAD AND NECK CANCER 87
  • 5.2.4 LEUKEMIA 87
  • 5.2.5 COLORECTAL CANCER 88
  • 5.2.6 LYMPHOMA 89
  • 5.2.7 OTHERS 90
    • 5.2.7.1 Breast cancer 90
    • 5.2.7.2 Myeloma 91
    • 5.2.7.3 Bladder cancer 91
• 5.3 INFLAMMATION 92
• 5.4 CENTRAL NERVOUS SYSTEM 94
• 5.5 OTHERS 97
  • 5.5.1 INFECTIOUS DISEASE 99
  • 5.5.2 OPHTHALMOLOGY 99
  • 5.5.3 BONE HEALTH 100

6 REGIONAL MARKET ANALYSIS 101

• 6.1 INTRODUCTION 101
• 6.2 NORTH AMERICA 103
• 6.3 EUROPE 104
• 6.4 ASIA PACIFIC 104
• 6.5 REST OF THE WORLD 105

7 COMPANY DEVELOPMENTS 106

• 7.1 INTRODUCTION 106
  • 7.1.1 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS MAJOR GROWTH STRATEGY OF PLAYERS 106
  • 7.1.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES 108
• 7.2 APPROVALS 129
• 7.3 MERGERS AND ACQUISITIONS 140
• 7.4 OTHER DEVELOPMENTS 146

8 MAJOR PLAYER PROFILES 150

• 8.1 ABBVIE, INC. 150
  • 8.1.1 OVERVIEW 150
  • 8.1.2 FINANCIALS 151
  • 8.1.3 PRODUCT PORTFOLIO 152
  • 8.1.4 KEY DEVELOPMENTS 153
  • 8.1.5 BUSINESS STRATEGY 155
  • 8.1.6 SWOT ANALYSIS 156
• 8.2 AMGEN, INC. 157
  • 8.2.1 OVERVIEW 157
  • 8.2.2 FINANCIALS 157
  • 8.2.3 PRODUCT PORTFOLIO 159
  • 8.2.4 KEY DEVELOPMENTS 161
  • 8.2.5 BUSINESS STRATEGY 165
  • 8.2.6 SWOT ANALYSIS 165
• 8.3 BIOGEN 166
  • 8.3.1 OVERVIEW 166
  • 8.3.2 FINANCIALS 166
  • 8.3.3 PRODUCT PORTFOLIO 167
  • 8.3.4 KEY DEVELOPMENTS 168
  • 8.3.5 BUSINESS STRATEGY 170
  • 8.3.6 SWOT ANALYSIS 171
• 8.4 BRISTOL-MYERS SQUIBB 172
  • 8.4.1 OVERVIEW 172
  • 8.4.2 FINANCIALS 173
  • 8.4.3 PRODUCT PORTFOLIO 176
  • 8.4.4 KEY DEVELOPMENTS 177
  • 8.4.5 BUSINESS STRATEGY 186
  • 8.4.6 SWOT ANALYSIS 187
• 8.5 CELGENE 188
  • 8.5.1 OVERVIEW 188
  • 8.5.2 FINANCIALS 189
  • 8.5.3 PRODUCT PORTFOLIO 190
  • 8.5.4 KEY DEVELOPMENTS 191
  • 8.5.5 BUSINESS STRATEGY 193
  • 8.5.6 SWOT ANALYSIS 194
• 8.6 JOHNSON & JOHNSON 195
  • 8.6.1 OVERVIEW 195
  • 8.6.2 FINANCIALS 196
  • 8.6.3 PRODUCT PORTFOLIO 198
  • 8.6.4 KEY DEVELOPMENTS 199
  • 8.6.5 BUSINESS STRATEGY 202
  • 8.6.6 SWOT ANALYSIS 203
• 8.7 MERCK & CO, INC. 204
  • 8.7.1 OVERVIEW 204
  • 8.7.2 FINANCIALS 205
  • 8.7.3 PRODUCT PORTFOLIO 207
  • 8.7.4 KEY DEVELOPMENTS 209
  • 8.7.5 BUSINESS STRATEGY 213
  • 8.7.6 SWOT ANALYSIS 214
• 8.8 NOVARTIS AG 215
  • 8.8.1 OVERVIEW 215
  • 8.8.2 FINANCIALS 216
  • 8.8.3 PRODUCT PORTFOLIO 218
  • 8.8.4 KEY DEVELOPMENTS 220
  • 8.8.5 BUSINESS STRATEGY 223
  • 8.8.6 SWOT ANALYSIS 224
• 8.9 PFIZER, INC. 225
  • 8.9.1 OVERVIEW 225
  • 8.9.2 FINANCIALS 226
  • 8.9.3 PRODUCT PORTFOLIO 228
  • 8.9.4 KEY DEVELOPMENTS 229
  • 8.9.5 BUSINESS STRATEGY 233
  • 8.9.6 SWOT ANALYSIS 234
• 8.10 ROCHE 235
  • 8.10.1 OVERVIEW 235
  • 8.10.2 FINANCIALS 236
  • 8.10.3 PRODUCT PORTFOLIO 240
  • 8.10.4 KEY DEVELOPMENTS 243
  • 8.10.5 BUSINESS STRATEGY 248
  • 8.10.6 SWOT ANALYSIS 249

LIST OF TABLES

TABLE 1 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 21

TABLE 2 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE,

(2013-2021) ($MN) 62

TABLE 3 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 64

TABLE 4 THERAPEUTIC VACCINES GLOBAL MAREKT REVENUE, BY REGION,

(2013-2021) ($MN) 72

TABLE 5 CHECKPOINT INHIBITORS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 77

TABLE 6 NON-SPECIFIC IMMUNOTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 78

TABLE 7 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 83

TABLE 8 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 84

TABLE 9 TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 85

TABLE 10 INFLAMMATION GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 93

TABLE 11 TOP SELLING DRUGS IN INFLAMMATION OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 94

TABLE 12 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 96

TABLE 13 TOP SELLING DRUGS IN CNS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 97

TABLE 14 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 98

TABLE 15 TOP SELLING DRUGS IN OTHERS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 99

TABLE 16 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2015) 108

TABLE 17 APPROVALS, (2014-2015) 130

TABLE 18 MERGERS AND ACQUISITIONS, (2014-2015) 141

TABLE 19 OTHER DEVELOPMENTS (2015) 146

TABLE 20 ABBVIE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 151

TABLE 21 ABBVIE, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 151

TABLE 22 ABBVIE, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 152

TABLE 23 AMGEN, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 157

TABLE 24 AMGEN, INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2012-2014) ($MN) 158

TABLE 25 AMGEN, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 159

TABLE 26 BIOGEN: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 166

TABLE 27 BIOGEN: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 167

TABLE 28 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES,

(2012-2014) ($MN) 173

TABLE 29 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY PRODUCT,

(2012-2014) ($MN) 174

TABLE 30 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 175

TABLE 31 CELGENE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 189

TABLE 32 CELGENE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 189

TABLE 33 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES,

(2012-2014) ($MN) 196

TABLE 34 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 197

TABLE 35 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 198

TABLE 36 MERCK & CO., INC.: TOTAL REVENUE AND R&D EXPENSES,

(2012-2014) ($MN) 205

TABLE 37 MERCK & CO., INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 206

TABLE 38 MERCK & CO., INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 207

TABLE 39 NOVARTIS AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 216

TABLE 40 NOVARTIS AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 217

TABLE 41 NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 218

TABLE 42 PFIZER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 226

TABLE 43 PFIZER, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 227

TABLE 44 PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 228

TABLE 45 ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN) 236

TABLE 46 ROCHE: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 237

TABLE 47 ROCHE: PHARMACEUTICALS REVENUE, BY APPLICATION,

(2012-2014) ($MN) 238

TABLE 48 ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 239

LIST OF FIGURES

FIGURE 1 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE, BY REGION,

(2013-2021) ($MN) 20

FIGURE 2 RESEARCH METHODOLOGY: IMMUNOTHERAPEUTICS MARKET 27

FIGURE 3 IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 28

FIGURE 4 IMMUNOTHERAPEUTICS MARKET: FORECASTING MODEL 29

FIGURE 5 IMMUNOTHERAPEUTICS MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION 30

FIGURE 6 IMMUNOTHERAPEUTICS GLOBAL MARKET: MARKET SEGMENTATION 37

FIGURE 7 MARKET DYNAMICS 38

FIGURE 8 IMMUNOTHERAPEUTICS MARKET: PORTER’S ANALYSIS 46

FIGURE 9 IMMUNOTHERAPEUTICS MARKET: PATENT FILLING BY MAJOR PLAYERS, (2011-2015) 55

FIGURE 10 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014 57

FIGURE 11 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE,

(2014 V’S 2021) ($MN) 61

FIGURE 12 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014 V’S 2021) ($MN) 82

FIGURE 13 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION,

(2013-2021) ($MN) 102

FIGURE 14 KEY GROWTH STRATEGIES, (2014-2015) 107

FIGURE 15 SWOT: ABBVIE, INC. 156

FIGURE 16 SWOT: AMGEN, INC. 165

FIGURE 17 SWOT: BIOGEN 171

FIGURE 18 SWOT: BRISTOL-MYERS SQUIBB 187

FIGURE 19 SWOT: CELGENE 194

FIGURE 20 SWOT: JOHNSON & JOHNSON 203

FIGURE 21 SWOT: MERCK & CO., INC. 214

FIGURE 22 SWOT: NOVARTIS AG 224

FIGURE 23 SWOT: PFIZER, INC. 234

FIGURE 24 SWOT: ROCHE 249